State of Lung Cancer: New Report Reveals Arkansas Among Worst in Nation for New Lung Cancer Cases

Today, the American Lung Association in Arkansas released the 2025 “State of Lung Cancer” report, which reveals that more needs to be done to end the burden of this devastating disease on families throughout the state. Lung cancer is the leading cause of cancer deaths here in Arkansas and across the U.S. The report finds Arkansas is 41st out of 51 in the nation for new lung cancer cases. 

The Lung Association’s eighth annual “State of Lung Cancer” report highlights how the toll of lung cancer varies by state and examines key indicators throughout the U.S., including new cases, survival, early diagnosis, surgical treatment, lack of treatment, screening rates and insurance coverage of comprehensive biomarker testing.

The report found that Arkansas ranks:

• 47 out of 51 in the nation for rate of new lung cancer cases, at 68.21 per 100,000. The national rate is 52.8 per 100,000.
• 33 out of 51 in the nation for lung cancer screening, at 16.6%. Lung cancer screening with annual low-dose CT scans for people at high risk can reduce the lung cancer death rate by up to 20%. Nationally, only 18.2% of people at high risk were screened.
• 41 out of 51 in the nation for smoking, at 15%.

“In the last decade, we have seen incredible progress, including increases in lung cancer survival and early detection rates. This means that more people in Arkansas are living longer after a lung cancer diagnosis,” said Laura Turner, director of advocacy for the American Lung Association. “While this progress gives us hope, early detection and survival rates are far too low in our state. Working to increase awareness and access to lung cancer screening and biomarker testing are critical to saving lives. This is why the state must step in to ensure their residents have access to the best lung cancer care.”

The “State of Lung Cancer” report also examines insurance coverage of comprehensive biomarker testing across the U.S. Lung cancer biomarker testing, sometimes referred to as tumor, molecular, genomic or genetic testing, looks for changes in the tumor's DNA. The results of the test may show biomarkers that can help determine what treatment options would be best for an individual patient. Insurance coverage of biomarker testing is important for removing a cost barrier to people with lung cancer, but coverage for biomarker testing is only required in some states. The report found that Arkansas requires coverage of biomarker testing, but only in some health plans.

The 2025 “State of Lung Cancer” report highlights opportunities for states to reduce the burden of lung cancer and encourages everyone to help end lung cancer. This year, the American Lung Association calls on Arkansas to expand comprehensive coverages so that all insurance plans, including Medicaid, are required to cover it. Learn more about the report and take action at Lung.org/solc.